A recent scientific investigation has highlighted potential health risks linked to a common ingredient found in many popular energy drinks. U.S. researchers have found that taurine, an amino acid frequently included in energy drinks like Red Bull and Celsius, could potentially heighten the risk of blood cancers. This amino acid, often incorporated into these beverages to enhance metabolism, can act as an energy source for leukemia cancer cells that originate in the bone marrow.
The study’s authors have advised consumers to exercise caution when consuming beverages containing taurine, which are widely available in supermarkets worldwide. The research, published in the scientific journal Nature, indicates that the potential risks and benefits of supplemental taurine should be carefully weighed, especially for individuals diagnosed with leukemia.
While the human body naturally produces taurine and it has been used to alleviate the side effects of chemotherapy in leukemia patients, researchers at the University of Rochester in New York have expressed concerns that additional intake could potentially worsen the blood cancer. The study emphasizes the importance of a comprehensive evaluation of the risks and benefits of extra taurine for leukemia patients, as well as for those who regularly consume energy drinks.
Despite the research still being in its preliminary stages, the scientists are optimistic that targeting taurine production in leukemia cells could provide a new treatment strategy for these aggressive diseases. Their experiments on mice and human leukemia cells have demonstrated that preventing taurine from entering cells could slow the disease’s progression.
The research is part of a broader investigation into taurine’s potential role in fueling other types of cancer, such as colorectal cancer. Taurine, which naturally occurs in protein-rich foods like meat and fish, is frequently used in energy drinks because it aids digestion, maintains proper hydration and electrolyte balances, and supports the overall function of the central nervous system.
The scientists studied mice with the SLC6A6 gene, which is responsible for transporting taurine throughout the body. They also transplanted human leukemia cells into these mice and discovered that a specific group of healthy bone marrow cells produces taurine, the environment where leukemia develops. The SLC6A6 gene then transports this taurine from the bone marrow to the leukemia cells.
As the cancer cells consume taurine, they undergo a process known as glycolysis, where cells break down glucose to produce energy. This process provides the energy cancer cells need to divide and multiply, potentially making leukemia more aggressive by increasing the number of cancer cells.
According to Cancer Australia, there were 5,202 new cases of leukemia diagnosed in Australia in 2022, with approximately 2,121 people dying from the disease in the same year. Currently, around 135,000 people in Australia are living with blood cancer or a related blood disorder.